Assessing the effects of ABBV-324 on liver and lung cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and efficacy of ABBV-324, an investigational drug, in treating adult patients with hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). Participants will be assigned to receive either ABBV-324 alone or in combination with lenvatinib, with the aim of determining the optimal dose and monitoring adverse events. The trial will enroll approximately 232 patients across 45 sites globally, focusing on those with advanced or unresectable disease. The study consists of a dose escalation phase followed by a dose optimization phase to assess the drug's effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Hepatocellular cancer (HCC) only: Child-Pugh A classification within 7 days before Cycle 1, Day 1 dosing.
* Laboratory values meeting the criteria outlined in the protocol.
* QT interval corrected for heart rate (QTc) \< 470 msec (using Fridericia's correction), no Grade 3 arrythmia, and no other clinically significant cardiac abnormalities.
* Measurable disease per RECIST version 1.1.
* Part 1 and Part 2 - participants with HCC meeting the following disease activity criteria:

  * Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology or cytology. Participants with fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma/HCC are not eligible to enroll.
  * Disease that is not amenable to surgical and/or locoregional therapies, or progressive disease after surgical and/or locoregional therapies. For participants who progressed after locoregional therapy for HCC, locoregional therapy must have been completed \>= 28 days prior to baseline scan for the current study.
  * Part 1: Failure of at least 1 prior systemic treatment for HCC.
  * Part 2: Failure of at least 1 prior systemic treatment consisting of an immune checkpoint inhibitor (CPI) containing regimen for HCC, including but not limited to, atezolizumab in combination with bevacizumab or tremelimumab in combination with durvalumab. Note: Participants who have received prior lenvatinib will not be eligible for Part 2.
* Part 1 only - participants with squamous-cell non-small cell lung cancer (LUSC) meeting the following disease activity criteria:

  * Advanced or metastatic LUSC that is not amenable to surgical resection.
  * Must have failed at least 1 prior line of therapy that included at least platinum-based chemotherapy and an immune CPI, and/or an appropriate targeted therapy (if applicable), or is not suitable for other approved therapeutic options that have demonstrated clinical benefit at the judgment of the investigator. Participants should have no more than 2 lines of prior cytotoxic chemotherapy excluding neoadjuvant and/or adjuvant. Participants who are intolerant of standard therapy are eligible.

Exclusion Criteria:

* Unresolved clinically significant adverse events (AEs) \> Grade 1 from prior anticancer therapy except for alopecia.
* Untreated brain or meningeal metastases (i.e., participants with history of metastases are eligible provided they do not require ongoing steroid treatment for cerebral edema and have shown clinical and radiographic stability for at least 14 days after definitive therapy). Participants may continue with antiepileptic therapy if required.
* History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.
* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.
* History of clinically significant, intercurrent lung-specific illnesses including, but not limited to:

  * Underlying pulmonary disorder (i.e., pulmonary emboli within 3 months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion, dependence on supplemental oxygen, etc.).
  * Any autoimmune, connective tissue or inflammatory disorders with documented or suspicious pulmonary involvement at Screening.
* Must have discontinued anticancer therapy with antineoplastic intent including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 14 days or 5 half lives of the drug (whichever is shorter) prior to the first dose of ABBV-324. Palliative radiation therapy for bone, skin or subcutaneous metastases with 10 fractions or less is permitted and not participant to a washout period.

Where it's running

• City of Hope National Medical Center /ID# 270526
  Duarte, California, United States Recruiting
• City of Hope - Orange County Lennar Foundation Cancer Center /ID# 276120
  Irvine, California, United States Recruiting
• USC Norris Comprehensive Cancer Center /ID# 271573
  Los Angeles, California, United States Recruiting
• University Of California Irvine Medical Center /ID# 270507
  Orange, California, United States Recruiting
• UCLA - Santa Monica /ID# 275995
  Santa Monica, California, United States Recruiting
• University of Chicago Medical Center /ID# 270517
  Chicago, Illinois, United States Recruiting

Study contacts

• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08634404 alone or with ipilimumab for adults with advanced hepatocellular carcinoma not removable by surgery

  This tests PF-08634404 by itself and together with ipilimumab in adults whose hepatocellular carcinoma is advanced and cannot be removed surgically.

  Recruiting at 60 sites Phase 1/2 Pfizer · Irvine, California and 59 other locations · NCT07227012

• ZW251 for advanced liver, lung, and germ cell cancers

  This will test whether ZW251, an antibody-drug conjugate that targets GPC3, is safe and can shrink tumors in adults with advanced hepatocellular carcinoma, squamous cell non-small cell lung cancer, or germ cell tumors.

  Recruiting at 25 sites Phase 1 Zymeworks BC Inc. · San Francisco, California and 24 other locations · NCT07164313

• Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy

  This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT06899152

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• GPC3 targeted CAR-T cell therapy for advanced liver cancer

  This study is testing a new immune therapy using modified T cells to see if it can help people with advanced liver cancer that has a specific marker called GPC3.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05003895

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.